Authors' replyBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6923.272b (Published 22 January 1994) Cite this as: BMJ 1994;308:272
- A Lees,
- J Head
- Department of Neurology, Middlesex Hospital, London W1N 8AA
- University College London Medical School, London WC1.
EDITOR, - The Parkinson's Disease Research Group in the United Kingdom is aware of the disadvantages of an open prospective study, but a double blind trial would not have been possible at the time that the study started as the group's aim was to follow up a large number of patients from the early stages of the disease to death.
As a result of Vilho Myllyla and Esa Heinonen's queries we have analysed our data further. At three years' follow up the median dose of levodopa was 500 mg in arm 1 (levodopa alone) and 375 mg in arm 2 (levodopa plus selegiline) and the mean doses were …